Myofibroblastoma of the breast is a rare benign tumor seen predominantly in men in the sixth to seventh decades of life. We present a case of breast myofibroblastoma in a man and describe the mammographic, sonographic, and MR findings.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00004728-199905000-00016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Myofibroblastoma of the breast mimicking carcinoma: a diagnostic challenge with a crucial role for histopathology and immunohistochemistry.
BMJ Case Rep
January 2025
Pathology, Shri B.M. Patil Medical College Hospital and Research Centre, BLDE (Deemed to be University), Vijayapura, Karnataka, India.
Myofibroblastoma is a rare mesenchymal tumour known for its benign nature but complex diagnostic pathway. A woman in her 40s presented with a painless breast mass, initially reported as a fibroadenoma on ultrasound mammography and as a benign to borderline phyllodes tumour on fine needle aspiration cytology. Contrast-enhanced CT was reported as carcinoma of the breast with Breast Imaging and Reporting Data System (BIRADS)-6.
View Article and Find Full Text PDFGiant low-grade myofibroblastic sarcoma of the male breast: case report and literature review.
Pol J Pathol
January 2025
Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology and Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan, Hubei, P. R. China.
Low-grade myofibroblastic sarcoma is an uncommon malignancy that can be difficult to identify and for which there is no unified treatment protocol. We report herein a case of an 81-year-old male who presented with a giant irregular breast mass and was diagnosed with low-grade myofibroblastic sarcoma. In this study we summarise the clinicopathological features of 13 reported cases of myofibroblastic sarcoma arising in the breast, present the diagnostic process and treatment procedure of our case, and discuss the differential diagnosis from other similar diseases, to provide constructive information and promote deep understanding of myofibroblastic sarcoma in the future.
View Article and Find Full Text PDFSingle-cell profiling transcriptomic reveals cellular heterogeneity and cellular crosstalk in breast cancer lymphatic node, bone, and brain metastases.
Sci Rep
January 2025
Department of Radiotherapy Oncology, The Fourth Hospital of Hebei Medical University, No. 169, Tianshan Street, Hebei, Shijiazhuang, 050035, Hebei Province, China.
Breast cancer is the most common malignant tumor in the world, and its metastasis is the main cause of death in breast cancer patients. However, the differences between primary breast cancer tissue and lymphatic node, bone, and brain metastases at the single-cell level are not fully understood. We analyzed the microenvironment heterogeneity in samples of primary breast cancer (n = 4), breast cancer lymphatic node metastasis (n = 4), breast cancer brain metastasis (n = 3), and breast cancer bone metastasis (n = 2) using single-cell sequencing data from the GEO database.
View Article and Find Full Text PDF4-Pyridone-3-carboxamide-1-β-D-ribonucleoside Reduces Cyclophosphamide Effects and Induces Endothelial Inflammation in Murine Breast Cancer Model.
Int J Mol Sci
December 2024
Department of Biochemistry, Medical University of Gdansk, 80-211 Gdańsk, Poland.
4-pyridone-3-carboxamide-1-β-D-ribonucleoside (4PYR) is a nicotinamide derivative, considered a new oncometabolite. 4PYR formation induced a cytotoxic effect on the endothelium. Elevated blood 4PYR concentration was observed in patients with cancer.
View Article and Find Full Text PDFValidation of biomarkers and clinical scores for the detection of uterine leiomyosarcoma: a case-control study with an update of pLMS.
BMC Cancer
January 2025
Department of Obstetrics and Gynecology, University Medicine Greifswald, Sauerbruchstr., Greifswald, 17475, Germany.
Background: The diagnosis of rare uterine leiomyosarcoma (uLMS) remains a challenge given the high incidence rates of benign uterine tumors such as leiomyoma (LM). In the last decade, several clinical scores and blood serum markers have been proposed. The aim of this study is to validate and update the pLMS clinical scoring system, evaluating the accuracy of the scoring system by Zhang et al.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!